1. Faecal microbiota transplantation (FMT) for Clostridium difficile infection (CDI) in immunocompromised (IC) pts: Efficacy and safety International, multi-centre, retrospective study: N=75 adult + 5 paediatric IC pts with CDI (79% outpatients): recurrent: 55% − refractory: 11% − severe (± recurrent/refractory): 34% → 32-item questionnaire soliciting demographic and pre- and post-FMT data Mean FU between FMT and data collection: 11 mo (range: 3-46 mo) Efficacy Kelly CR et al. Am J Gastroenterol 2014;109:1065-71 1 of 2 IBD: inflammatory bowel disease; IS: immunosuppressive

2. Faecal microbiota transplantation (FMT) for Clostridium difficile infection (CDI) in immunocompromised (IC) pts: Efficacy and safety Safety (≤12 wk post-FMT) No infections related to FMT within 12 wk after FMT No significant ≠ in rate of AEs or SAEs between pts with and without IBD In IC patients, FMT appears to be effective for the Tx of CDI, with few SAEs and Tx-related AEs, and no related infectious complications Kelly CR et al. Am J Gastroenterol 2014;109:1065-71 2 of 2

3. Faecal microbiota transplantation (FMT) for Clostridium difficile infection (CDI) in immunocompromised (IC) pts: Efficacy and safety Safety (≤12 wk post-FMT) No infections related to FMT within 12 wk after FMT No significant ≠ in rate of AEs or SAEs between pts with and without IBD In IC patients, FMT appears to be effective for the Tx of CDI, with few SAEs and Tx-related AEs, and no related infectious complications Kelly CR et al. Am J Gastroenterol 2014;109:1065-71

4. Impact of donor cytomegalovirus (CMV) serological status on outcome of haematopoietic stem cell transplant (HSCT) Retrospective study (European Group for Blood and Marrow Transplantation database; 1992-2008): N=49,542 HSCT pts: Seropositive (R+): N=29,349 / Seronegative (R-): N=20,193 Ljungman P et al. Clin Infect Dis 2014;59:473-81 1 of 2 Estimated 5-yr overall survival: Kaplan-Meier analysis; HR, P-values: multivariate Cox regression model

5. Impact of donor cytomegalovirus (CMV) serological status on outcome of haematopoietic stem cell transplant (HSCT) Result also valid when analysis was restricted to pts with myeloablative conditioning from yr 2000 onwards (N=21,813): HR=0.91; P=0.02 Ljungman P et al. Clin Infect Dis 2014;59:473-81 2 of 2 Selecting a D+ unrelated donor may negatively impact survival compared with a D- in R- pts, but may positively impact survival in R+ pts receiving a myeloablative conditioning regimen

6. PTX3 SNPs: prognostic value for invasive aspergillosis in haematopoietic stem cell transplant (HSCT) pts Long pentraxin 3 (PTX3): soluble pattern-recognition receptor involved in immune resistance to Aspergillus fumigatus Single-centre discovery study (2003-2011; Italy): N=268 adult pts undergoing HSCT + respective donors (98% related) → screened for PTX3 single nucleotide polymorphisms (SNPs) Multivariate analysis: Independent predictors of risk of invasive aspergillosis: Cunha C et al. New Engl J Med 2014;370:421-32 1 of 2 HR for presence vs absence of genotype or haplotype; adjusted for HLA- matching status, use or non-use of total-body irradiation in the myeloablative conditioning, and antifungal prophylaxis

7. PTX3 SNPs: prognostic value for invasive aspergillosis in haematopoietic stem cell transplant (HSCT) pts Multi-centre confirmation study: 107 pts with invasive aspergillosis + 223 matched controls Multivariate analysis: Independent predictors of risk of invasive aspergillosis: Functional analysis: PTX3 deficiency in h2/h2 neutrophils → instability of messenger RNA → ability to phagocytose conidia of A. fumigatus and clear fungus: significantly impaired Genetic deficiency of PTX3 may be associated with an increased risk of invasive aspergillosis in pts treated with HSCT, presumably by affecting antifungal capacity of neutrophils Cunha C et al. New Engl J Med 2014;370:421-32 2 of 2 OR for presence vs absence of genotype or haplotype; adjusted for HLA-matching status, use or non-use of total-body irradiation in the myeloablative conditioning